Goldman Sachs Group Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,294,210 shares of ARWR stock, worth $25.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,294,210

Previous 1,272,901 1.67%

Holding current value

$25.8 Million

Previous $24.6 Million 1.27%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$17.7 - $26.34 $377,169 - $561,279	21,309 Added 1.67%	1,294,210 $24.3 Million
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $183,126 - $279,418	9,459 Added 0.75%	1,272,901 $24.6 Million
Q2 2024 Aug 13, 2024	BUY	$21.87 - $28.24 $4.68 Million - $6.04 Million	213,903 Added 20.38%	1,263,442 $32.8 Million
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $338,165 - $490,657	-12,428 Reduced 1.17%	1,049,539 $30 Million
Q4 2023 Feb 13, 2024	BUY	$21.2 - $31.03 $13 Million - $19 Million	613,067 Added 136.57%	1,061,967 $32.5 Million
Q3 2023 May 14, 2024	SELL	$26.2 - $36.08 $16.1 Million - $22.1 Million	-613,067 Reduced 57.73%	448,900 $12.1 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $5.04 Million - $6.93 Million	-192,186 Reduced 29.98%	448,900 $12.1 Million
Q2 2023 May 14, 2024	SELL	$25.16 - $41.38 $1.8 Million - $2.96 Million	-71,505 Reduced 10.03%	641,086 $22.9 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $1.8 Million - $2.96 Million	-71,505 Reduced 10.03%	641,086 $22.9 Million
Q1 2023 May 14, 2024	SELL	$23.68 - $38.51 $853,948 - $1.39 Million	-36,062 Reduced 4.82%	712,591 $18.1 Million
Q1 2023 May 11, 2023	SELL	$23.68 - $38.51 $853,948 - $1.39 Million	-36,062 Reduced 4.82%	712,591 $18.1 Million
Q4 2022 May 14, 2024	SELL	$28.0 - $40.56 $7.69 Million - $11.1 Million	-274,668 Reduced 26.84%	748,653 $30.4 Million
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $7.69 Million - $11.1 Million	-274,668 Reduced 26.84%	748,653 $30.4 Million
Q3 2022 May 14, 2024	BUY	$29.63 - $48.31 $1.38 Million - $2.26 Million	46,737 Added 4.79%	1,023,321 $33.8 Million
Q3 2022 Nov 10, 2022	BUY	$29.63 - $48.31 $1.38 Million - $2.26 Million	46,737 Added 4.79%	1,023,321 $33.8 Million
Q2 2022 May 14, 2024	SELL	$27.79 - $50.61 $2.37 Million - $4.32 Million	-85,383 Reduced 8.04%	976,584 $34.4 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $5.33 Million - $9.72 Million	191,968 Added 24.47%	976,584 $34.4 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $5.88 Million - $10.4 Million	148,438 Added 23.33%	784,616 $36.1 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $6.89 Million - $9.79 Million	-118,659 Reduced 15.72%	636,178 $42.2 Million
Q3 2021 Nov 10, 2021	BUY	$58.38 - $84.96 $44.1 Million - $64.1 Million	754,837 New	754,837 $47.1 Million

Others Institutions Holding ARWR

# of Institutions

304

Shares Held

96.2M

Call Options Held

388K

Put Options Held

420K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.11B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Arrowhead Pharmaceuticals, Inc. Transaction History